IL4 and type 1 diabetes mellitus: In contrast to the results observed in the STZ model, NOD mice that received oral treatment with L. lactis MG1363 FnBPA+ (pValac::dts::IL-4) and L. lactis MG1363 FnBPA+ (pValac::IL-10) (F-IL-4/IL-10-NOD group) showed normoglycemia (glycemic levels less than 200 mg/dL) until the end of the experimental period (Figure 3(a)) and treatment protected NOD mice from T1D development.